BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35382656)

  • 21. High sex determining region Y-box 2 (SOX2) expression correlates with absence of nodal metastasis in esophageal squamous cell carcinoma.
    Chuang WY; Chang YS; Chao YK; Yeh CJ; Liu YH; Tseng CK; Chang HK; Wan YL; Hsueh C
    Int J Clin Exp Pathol; 2015; 8(8):9248-55. PubMed ID: 26464673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of tumor-associated autoantibodies panel in combination with traditional tumor markers for lung cancer.
    Xu Y; Zhang W; Xia T; Liu Y; Bi Z; Guo L; Xie W; Xiang Y; Xu Z; Yu Z; Li Y; Bai L
    Front Oncol; 2023; 13():1022331. PubMed ID: 36874112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma.
    Shahryari A; Rafiee MR; Fouani Y; Oliae NA; Samaei NM; Shafiee M; Semnani S; Vasei M; Mowla SJ
    Stem Cells; 2014 Jan; 32(1):126-34. PubMed ID: 24105929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
    Tang ZM; Ling ZG; Wang CM; Wu YB; Kong JL
    PLoS One; 2017; 12(7):e0182117. PubMed ID: 28750095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mortality Risk factors and SOX2 and mTOR expression in Patients with Esophageal Cancer.
    Yu G; Yuexin Y; Yin L; Yiyin Z; Mei K; Liyang Z; Lei X; Fan W
    Cell Mol Biol (Noisy-le-grand); 2022 Jan; 67(4):346-357. PubMed ID: 35809269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative serum immunoglobulin G and A antibodies to Porphyromonas gingivalis are potential serum biomarkers for the diagnosis and prognosis of esophageal squamous cell carcinoma.
    Gao SG; Yang JQ; Ma ZK; Yuan X; Zhao C; Wang GC; Wei H; Feng XS; Qi YJ
    BMC Cancer; 2018 Jan; 18(1):17. PubMed ID: 29298684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
    Honing J; Pavlov KV; Mul VE; Karrenbeld A; Meijer C; Faiz Z; Smit JK; Hospers GA; Burgerhof JG; Kruyt FA; Kleibeuker JH; Plukker JT
    Radiother Oncol; 2015 Oct; 117(1):152-8. PubMed ID: 26364884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SOX2/SALL4 stemness axis modulates Notch signaling genes to maintain self-renewal capacity of esophageal squamous cell carcinoma.
    Forghanifard MM; Kasebi P; Abbaszadegan MR
    Mol Cell Biochem; 2021 Feb; 476(2):921-929. PubMed ID: 33098486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.
    Dong J; Zeng BH; Xu LH; Wang JY; Li MZ; Zeng MS; Liu WL
    J Transl Med; 2010 Sep; 8():81. PubMed ID: 20813067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.
    Guan S; Liu B; Zhang C; Lee KH; Sun S; Wei J
    Clin Transl Oncol; 2013 Oct; 15(10):825-9. PubMed ID: 23423807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic value of serum tumor-associated autoantibodies in esophageal cancer.
    Xiao K; Ma X; Wang Y; Zhu C; Guo L; Lu R
    Biomark Med; 2021 Oct; 15(15):1333-1343. PubMed ID: 34541870
    [No Abstract]   [Full Text] [Related]  

  • 33. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
    van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
    Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SOX2 Promotes the Epithelial to Mesenchymal Transition of Esophageal Squamous Cells by Modulating Slug Expression through the Activation of STAT3/HIF-α Signaling.
    Gao H; Teng C; Huang W; Peng J; Wang C
    Int J Mol Sci; 2015 Sep; 16(9):21643-57. PubMed ID: 26370982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
    Kunizaki M; Hamasaki K; Wakata K; Tobinaga S; Sumida Y; Hidaka S; Yasutake T; Miyazaki T; Matsumoto K; Yamasaki T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2018 Mar; 38(3):1807-1813. PubMed ID: 29491120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RCC2 Promotes Esophageal Cancer Growth by Regulating Activity and Expression of the Sox2 Transcription Factor.
    Calderon-Aparicio A; Yamamoto H; De Vitto H; Zhang T; Wang Q; Bode AM; Dong Z
    Mol Cancer Res; 2020 Nov; 18(11):1660-1674. PubMed ID: 32801160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of the prognostic value of immune gene signature and infiltrating immune cells for esophageal cancer patients.
    Wang L; Wei Q; Zhang M; Chen L; Li Z; Zhou C; He M; Wei M; Zhao L
    Int Immunopharmacol; 2020 Oct; 87():106795. PubMed ID: 32707495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma.
    Wang Q; He W; Lu C; Wang Z; Wang J; Giercksky KE; Nesland JM; Suo Z
    Anticancer Res; 2009 Apr; 29(4):1233-41. PubMed ID: 19414369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Diagnosis Model for Early Lung Nodules Based on a Seven Autoantibodies Panel and Imaging Features.
    Xu L; Chang N; Yang T; Lang Y; Zhang Y; Che Y; Xi H; Zhang W; Song Q; Zhou Y; Yang X; Yang J; Qu S; Zhang J
    Front Oncol; 2022; 12():883543. PubMed ID: 35530343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
    Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
    BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.